Explain why diversity is important in clinical trials.
Understand the barriers that limit the participation of patients from underrepresented groups in clinical trials.
Identify strategies that health care professionals (HCPs) can use to overcome these barriers.
Summary
Historically, diversity has not always been considered in clinical trials, but ignoring diversity may contribute to missed opportunities to fully understand the factors that lead to disease or improved health outcomes. Diversity in clinical trials may provide results that are more generalizable, reduce disparities in health outcomes, and optimize treatment based on individual differences. This presentation will explore barriers to the inclusion of patients from underrepresented groups in clinical trials, including patient barriers, HCP-related barriers, and barriers resulting from the clinical trial itself. The presenter will explore several strategies that may be used to help promote diversity in clinical trials.
Contact a Merck Academy Team Member
To request that a Merck Academy program be scheduled at your institution, or for questions
about the program, please contact USMA Operations - NPASTRATOPS@merck.com
